search results for 
Logo

Fresenius SE & Co. KGaA
Consolidated segment reporting

by business segment


  Fresenius Medical Care Fresenius Kabi Fresenius Helios Fresenius Vamed Corporate/Other1 Fresenius Group
€ in millions 2011 2010 Change 2011 2010 Change 2011 2010 Change 2011 2010 Change 2011 2010 Change 2011 2010 Change
1 Including special items from the acquisition of APP Pharmaceuticals, Inc.
The consolidated segment reporting by business segment is an integral part of the notes.
The following notes are an integral part of the consolidated financial statements.
Sales 9,192 9,091 1% 3,964 3,672 8% 2,665 2,520 6% 737 713 3% -36 -24 -50% 16,522 15,972 3%
thereof contribution to consolidated sales 9,177 9,088 1% 3,916 3,629 8% 2,665 2,520 6% 737 713 3% 27 22 23% 16,522 15,972 3%
thereof intercompany sales 15 3 -- 48 43 12% 0 0   - - -- -63 -46 -37% 0 0  
contribution to consolidated sales 56% 57%   24% 23%   16% 16%   4% 4%   0% 0%   100% 100%  
EBITDA 1,891 1,830 3% 955 893 7% 369 318 16% 51 49 4% -29 -33 12% 3,237 3,057 6%
Depreciation and amortization 400 379 6% 152 156 -3% 99 83 19% 7 8 -13% 16 13 23% 674 639 5%
EBIT 1,491 1,451 3% 803 737 9% 270 235 15% 44 41 7% -45 -46 2% 2,563 2,418 6%
Net interest -213 -211 -1% -278 -279 0% -51 -55 7% 2 2 0% 9 -23 139% -531 -566 6%
Income taxes -432 -436 1% -145 -142 -2% -43 -37 -16% -11 -12 8% 27 46 -41% -604 -581 -4%
Net income attributable to Fresenius SE & Co. KGaA 770 738 4% 354 294 20% 163 131 24% 34 30 13% -631 -571 -11% 690 622 11%
                                     
Operating cash flow 1,039 1,032 1% 462 567 -19% 294 311 -5% -83 47 -- -23 -46 50% 1,689 1,911 -12%
Cash flow before acquisitions and dividends 629 649 -3% 289 401 -28% 138 150 -8% -89 38 -- -36 -60 40% 931 1,178 -21%
                                     
Total assets 15,096 12,793 18% 7,282 6,860 6% 3,495 3,270 7% 594 549 8% -146 105 -- 26,321 23,577 12%
Debt 5,573 4,400 27% 4,395 4,298 2% 1,104 1,096 1% 44 16 175% -1,317 -1,026 -28% 9,799 8,784 12%
Capital expenditure, gross 429 395 9% 177 174 2% 157 166 -5% 7 9 -22% 13 14 -7% 783 758 3%
Acquisitions, gross/investments 1,429 596 140% 11 31 -65% 45 13 -- 3 5 -40% 124 -1 -- 1,612 644 150%
                                     
Research and development expenses 80 73 10% 162 143 13% - - -- 0 0   25 28 -11% 267 244 9%
Employees (per capita on balance sheet date) 83,476 77,442 8% 24,106 22,851 5% 37,198 33,321 12% 3,724 3,110 20% 847 828 2% 149,351 137,552 9%
                                     
Key figures                                    
EBITDA margin 20.6% 20.1%   24.1% 24.3%   13.8% 12.6%   6.9% 6.9%         19.6% 19.1%  
EBIT margin 16.2% 16.0%   20.3% 20.1%   10.1% 9.3%   6.0% 5.8%         15.5% 15.1%  
Depreciation and amortization in % of sales 4.4% 4.2%   3.8% 4.2%   3.7% 3.3%   0.9% 1.1%         4.1% 4.0%  
Operating cash flow in % of sales 11.3% 11.4%   11.7% 15.4%   11.0% 12.3%   -11.3% 6.6%         10.2% 12.0%  
ROOA 12.0% 12.5%   12.4% 11.9%   8.4% 7.8%   16.0% 22.2%         10.9% 11.6%  

  Fresenius Medical Care Fresenius Kabi Fresenius Helios Fresenius Vamed Corporate/Other1 Fresenius Group
€ in millions 2011 2010 Change 2011 2010 Change 2011 2010 Change 2011 2010 Change 2011 2010 Change 2011 2010 Change
1 Including special items from the acquisition of APP Pharmaceuticals, Inc.
The consolidated segment reporting by business segment is an integral part of the notes.
The following notes are an integral part of the consolidated financial statements.
Sales 9,192 9,091 1% 3,964 3,672 8% 2,665 2,520 6% 737 713 3% -36 -24 -50% 16,522 15,972 3%
thereof contribution to consolidated sales 9,177 9,088 1% 3,916 3,629 8% 2,665 2,520 6% 737 713 3% 27 22 23% 16,522 15,972 3%
thereof intercompany sales 15 3 -- 48 43 12% 0 0   - - -- -63 -46 -37% 0 0  
contribution to consolidated sales 56% 57%   24% 23%   16% 16%   4% 4%   0% 0%   100% 100%  
EBITDA 1,891 1,830 3% 955 893 7% 369 318 16% 51 49 4% -29 -33 12% 3,237 3,057 6%
Depreciation and amortization 400 379 6% 152 156 -3% 99 83 19% 7 8 -13% 16 13 23% 674 639 5%
EBIT 1,491 1,451 3% 803 737 9% 270 235 15% 44 41 7% -45 -46 2% 2,563 2,418 6%
Net interest -213 -211 -1% -278 -279 0% -51 -55 7% 2 2 0% 9 -23 139% -531 -566 6%
Income taxes -432 -436 1% -145 -142 -2% -43 -37 -16% -11 -12 8% 27 46 -41% -604 -581 -4%
Net income attributable to Fresenius SE & Co. KGaA 770 738 4% 354 294 20% 163 131 24% 34 30 13% -631 -571 -11% 690 622 11%
                                     
Operating cash flow 1,039 1,032 1% 462 567 -19% 294 311 -5% -83 47 -- -23 -46 50% 1,689 1,911 -12%
Cash flow before acquisitions and dividends 629 649 -3% 289 401 -28% 138 150 -8% -89 38 -- -36 -60 40% 931 1,178 -21%
                                     
Total assets 15,096 12,793 18% 7,282 6,860 6% 3,495 3,270 7% 594 549 8% -146 105 -- 26,321 23,577 12%
Debt 5,573 4,400 27% 4,395 4,298 2% 1,104 1,096 1% 44 16 175% -1,317 -1,026 -28% 9,799 8,784 12%
Capital expenditure, gross 429 395 9% 177 174 2% 157 166 -5% 7 9 -22% 13 14 -7% 783 758 3%
Acquisitions, gross/investments 1,429 596 140% 11 31 -65% 45 13 -- 3 5 -40% 124 -1 -- 1,612 644 150%
                                     
Research and development expenses 80 73 10% 162 143 13% - - -- 0 0   25 28 -11% 267 244 9%
Employees (per capita on balance sheet date) 83,476 77,442 8% 24,106 22,851 5% 37,198 33,321 12% 3,724 3,110 20% 847 828 2% 149,351 137,552 9%
                                     
Key figures                                    
EBITDA margin 20.6% 20.1%   24.1% 24.3%   13.8% 12.6%   6.9% 6.9%         19.6% 19.1%  
EBIT margin 16.2% 16.0%   20.3% 20.1%   10.1% 9.3%   6.0% 5.8%         15.5% 15.1%  
Depreciation and amortization in % of sales 4.4% 4.2%   3.8% 4.2%   3.7% 3.3%   0.9% 1.1%         4.1% 4.0%  
Operating cash flow in % of sales 11.3% 11.4%   11.7% 15.4%   11.0% 12.3%   -11.3% 6.6%         10.2% 12.0%  
ROOA 12.0% 12.5%   12.4% 11.9%   8.4% 7.8%   16.0% 22.2%         10.9% 11.6%  

by region


  Europe North America Asia-Pacific Latin America Africa Fresenius Group
€ in millions 2011 2010 Change 2011 2010 Change 2011 2010 Change 2011 2010 Change 2011 2010 Change 2011 2010 Change
The consolidated segment reporting by region is an integral part of the notes.
The following notes are an integral part of the consolidated financial statements.
Sales 6,919 6,515 6% 6,762 7,020 -4% 1,582 1,307 21% 899 814 10% 360 316 14% 16,522 15,972 3%
contribution to consolidated sales 42% 41%   41% 44%   10% 8%   5% 5%   2% 2%   100% 100%  
EBIT 758 723 5% 1,382 1,347 3% 251 205 22% 125 107 17% 47 36 31% 2,563 2,418 6%
Depreciation and amortization 322 294 10% 268 265 1% 50 47 6% 29 27 7% 5 6 -17% 674 639 5%
                                     
Total assets 9,759 8,935 9% 13,670 12,152 12% 1,888 1,610 17% 877 755 16% 127 125 2% 26,321 23,577 12%
Capital expenditure, gross 422 400 6% 210 223 -6% 69 73 -5% 71 52 37% 11 10 10% 783 758 3%
Acquisitions, gross/investments 924 267 -- 596 277 115% 75 89 -16% 17 11 55% - - -- 1,612 644 150%
                                     
Employees (per capita on balance sheet date) 74,415 66,179 12% 47,701 46,082 4% 13,134 12,258 7% 12,754 11,726 9% 1,347 1,307 3% 149,351 137,552 9%

  Europe North America Asia-Pacific Latin America Africa Fresenius Group
€ in millions 2011 2010 Change 2011 2010 Change 2011 2010 Change 2011 2010 Change 2011 2010 Change 2011 2010 Change
The consolidated segment reporting by region is an integral part of the notes.
The following notes are an integral part of the consolidated financial statements.
Sales 6,919 6,515 6% 6,762 7,020 -4% 1,582 1,307 21% 899 814 10% 360 316 14% 16,522 15,972 3%
contribution to consolidated sales 42% 41%   41% 44%   10% 8%   5% 5%   2% 2%   100% 100%  
EBIT 758 723 5% 1,382 1,347 3% 251 205 22% 125 107 17% 47 36 31% 2,563 2,418 6%
Depreciation and amortization 322 294 10% 268 265 1% 50 47 6% 29 27 7% 5 6 -17% 674 639 5%
                                     
Total assets 9,759 8,935 9% 13,670 12,152 12% 1,888 1,610 17% 877 755 16% 127 125 2% 26,321 23,577 12%
Capital expenditure, gross 422 400 6% 210 223 -6% 69 73 -5% 71 52 37% 11 10 10% 783 758 3%
Acquisitions, gross/investments 924 267 -- 596 277 115% 75 89 -16% 17 11 55% - - -- 1,612 644 150%
                                     
Employees (per capita on balance sheet date) 74,415 66,179 12% 47,701 46,082 4% 13,134 12,258 7% 12,754 11,726 9% 1,347 1,307 3% 149,351 137,552 9%

Continue reading:
Notes